Clinical trials: Elective Percutaneous Coronary Intervention
Angioplasty, Transluminal, Percutaneous Coronary
Efficacy Study of Cilostazol Loading in Elective Percutaneous Coronary Intervention
The purpose of this study is to investigate the effect of cilostazol loading before planned PCI on major adverse cardiac and cerebrovascular events in patients with coronary artery disease.
- Trial name
- PRECEDE (NCT00938522)
- Testing
- Cilostazol
- Where
- South Korea
- Volunteers
- 400 people
- Sponsor
- Samsung Medical Center
ST Segment Elevation Myocardial Infarction, Elective Percutaneous Coronary Intervention
Prevention of Coronary Slow Flow or No-Reflow During EPCI in Patients With Acute STEMI
Elective percutaneous coronary intervention (EPCI) is the common treatment of ST segment elevation myocardial infarction (STEMI).Slow flow / no-reflow phenomenon following EPCI in STEMI patients has been a serious and common…
- Trial name
- NOSLOWFLOW-Ⅱ (NCT03406832)
- Testing
- Nitroprusside Sodium, Tirofiban Hydrochloride, Heparinized saline
- Where
- 28 sites in China
- Volunteers
- 1,000 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Nephropathy
A Randomized Trial of Rosuvastatin in Elective Angioplasty to Prevent Contrast-induced Nephropathy (CLEAR-CIN).
The investigators analyzed the HMG-CoA reductase inhibitor, rosuvastatin, for the prevention of contrast-medium-induced nephropathy in patients undergoing primary angioplasty.
- Trial name
- CLEAR-CIN (NCT02737319)
- Testing
- Rosuvastatin
- Where
- Brazil
- Volunteers
- 493 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Coronary Artery Disease
Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function
Adequate platelet inhibition before percutaneous coronary intervention (PCI) reduces peri-procedural and long-term ischemic complications.
- Trial name
- NCT00693069
- Testing
- Clopidogrel
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
Percutaneous Coronary Intervention, Ischemic Symptoms
SAFE-PCI for Women
The hypothesis of the SAFE-PCI for women trial is that, compared with transfemoral PCI, transradial PCI will result in a significant reduction in bleeding and vascular complications.
- Trial name
- SAFE-PCI (NCT01406236)
- Testing
- Transradial PCI, Transfemoral PCI
- Volunteers
- 1,787 people
- Sponsor
- Duke University
Coronary Artery Disease
A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction
Despite the relative safety of PCI with new generation stents, peri-PCI thrombotic complications, including myocardial infarction and myocardial injury, are common in elective PCI, occurring in up to 30% of patients.
- Trial name
- NCT05332262
- Testing
- Assessment of platelet reactivity, Troponin measurement
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- University of Florida
Procedural Anxiety, Coronary Artery Disease
Video-based Intervention to Reduce Anxiety in Patients Undergoing Elective PCI
This study aims to evaluate the effectiveness of a video-based educational intervention in reducing anxiety among hospitalised patients scheduled for elective percutaneous coronary intervention (PCI).
- Conditions
- Procedural Anxiety, Coronary Artery Disease, Percutaneous Coronary Intervention Patients
- Trial name
- NCT07485088
- Testing
- Video intervention
- Where
- Singapore
- Volunteers
- 144 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
Right Coronary Artery Percutaneous Coronary Intervention, Right Ventricular Diastolic Dysfunction
Diastolic RV EvAluation With Millar Catheter to Investigate the Effect of Glucagon-Like Peptide-1 (GLP-1) on Right Ventricular Function During Elective Coronary Angioplasty and Stenting
The heart requires nutrients and oxygen carried in the blood to generate energy for healthy pump function. Blood is supplied via heart vessels called coronary arteries.
- Trial name
- DREAM GLP-1 (NCT02236299)
- Testing
- Right Coronary Artery Percutaneous Coronary Intervention, GLP-1 Infusion
- Where
- United Kingdom
- Volunteers
- 30 people
- Sponsor
- Papworth Hospital NHS Foundation Trust
Coronary Arteriosclerosis
Study of the Effect of omega3 on Biomarkers of Cardiac Necrosis (CKMB and Troponin I) and Inflammation Marker (CRP) After Elective Percutaneous Coronary Intervention (PCI)
The purpose of this study is to investigate the effect of omega 3 on biomarkers of cardiac necrosis(CKMB and troponin I) and inflammation marker CRP.
- Trial name
- NCT01521845
- Testing
- omega 3
- Where
- Iran
- Volunteers
- 104 people
- Sponsor
- Shahid Beheshti University of Medical Sciences
Coronary Disease
RIAPRE - Non-interventional Registry of Anticoagulation Treatment (BI-006-IT)
RIAPRE is a non-interventional registry to be settled in Italy with the purpose of collecting data on 600 cases of high risk elective percutaneous coronary intervention (PCI) patients treated with an anticoagulation regime…
- Trial name
- NCT00317343
- Testing
- Bivalirudin (thrombin specific anticoagulant)
- Sponsor
- Nycomed
Angioplasty, Coronary
Safety of Same Day Discharge After Elective Percutaneous Coronary Intervention
Study intends to determine if there is any difference in the occurrence of major adverse cardiology events in patients discharged on the same day as their elective cardiac angioplasty or discharged one day after their…
- Trial name
- NCT02214082
- Testing
- Same Day Discharge
- Where
- Pakistan
- Volunteers
- 210 people
- Sponsor
- Indus Hospital and Health Network
High-risk Percutaneous Coronary Intervention
Impella ECP Early Feasibility Study
The Impella ECP EFS is a prospective, multicenter, single-arm, feasibility study evaluating the safety of the Impella ECP device in adult patients undergoing an elective or urgent high-risk percutaneous coronary intervention.
- Trial name
- ECP EFS (NCT04477603)
- Testing
- Impella ECP
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- Abiomed Inc.
Stable Coronary Artery Disease
Intracoronary Stenting and Antithrombotic Regimen: Lesion Platelet Adhesion as Selective Target of Endovenous Revacept
The main objective is to evaluate the efficacy and safety of treatment with 2 doses (80 and 160 mg) of Revacept versus placebo in patients with stable coronary artery disease undergoing PCI.
- Trial name
- ISAR-PLASTER (NCT03312855)
- Testing
- Revacept 80 mg, Revacept 160 mg
- Where
- 8 sites in Germany
- Volunteers
- 334 people
- Sponsor
- Deutsches Herzzentrum Muenchen
Coronary Artery Disease
Colchicine Protective Effect in Patients Undergoing Percutaneous Coronary Intervention (COLCHICINE-PROTECT)
The goal of this clinical trial is to evaluate the colchicine protective effect in patients undergoing Percutaneous Coronary Intervention (PCI).
- Trial name
- NCT05739929
- Testing
- Colchicine 0.5 MG Oral Tablet
- Where
- Egypt
- Volunteers
- 400 people
- Sponsor
- Helwan University
Coronary Artery Disease
Myocardial Injury After Elective Coronary Stenting
This pilot study aims to identify patients at moderate to high risk for peri-procedural (type 4) myocardial infarction or injury after after undergoing an elective coronary intervention (PCI) as measured by high sensitivity…
- Trial name
- NCT01986621
- Where
- Germany
- Volunteers
- 530 people
- Sponsor
- University Hospital Heidelberg
Coronary Artery Disease, Myocardial Ischemia
Role of Plavix in Hemorrhagic and Ischemic Complications of Catheterization.
Patients who have stents placed in their coronary arteries require treatment with at least two medications to prevent platelets from sticking to the stainless steel stent and forming a blood clot that can result in a heart…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Bleeding
- Trial name
- NCT00421252
- Testing
- clopidogrel 600 mg, arterial access sheath
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Beth Israel Deaconess Medical Center
Coronary Artery Disease, Myocardial Ischemia
Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting
The new P2Y12 inhibitors prasugrel (Efient®-Effient®) and ticagrelor (Brilique®-Brilinta®) have shown promising results in the respective TRITON and PLATO trials making of prasugrel and ticagrelor recommended first line…
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Myocardial Infarction, Stent Thrombosis
- Trial name
- ALPHEUS (NCT02617290)
- Testing
- Ticagrelor, Clopidogrel
- Where
- France
- Volunteers
- 1,900 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ischemic Heart Disease
Clopidogrel Only Before Percutaneous Coronary Intervention or Before Every Coronarography?
Clopidogrel pre-treatment before planned percutaneous coronary intervention was proved to reduce periprocedural complications. However, the vast majority of patients in the current interventional cardiology practice do not…
- Trial name
- NCT00432120
- Testing
- clopidogrel
- Where
- Czechia
- Sponsor
- Charles University, Czech Republic
Coronary Artery Disease, Angina, Unstable
Study on Safety and Effectiveness of Three Doses of Argatroban as Anticoagulant in Percutaneous Coronary Intervention (PCI)
This is a phase II multi-centre study in 140 patients undergoing elective PCI to obtain the information on dose-response of argatroban in pharmacodynamic markers and to assess the anticoagulation, safety and efficacy of…
- Trial name
- NCT00508924
- Testing
- Argatroban, Heparin
- Where
- 8 sites in Belgium, Germany
- Volunteers
- 140 people
- Sponsor
- Tanabe Pharma Corporation
Coronary Heart Disease
Safety and Efficacy of Prolonged Use of Bivalirudin 4 Hours After ePCI (COBER Study)
Since the development of percutaneous coronary intervention (PCI) in patients with coronary heart disease (CHD), unfractionated heparin (UFH) and low molecular weight heparin (LWMH) have been the preferred anticoagulants in…
- Trial name
- NCT04120961
- Testing
- prolonged continuous use of bivalirudin, bivalirudin use during ePCI
- Where
- China
- Volunteers
- 330 people
- Sponsor
- Nanjing First Hospital, Nanjing Medical University